Solentim in 2019: The Highlights
Solentim, the world leader in instruments and workflow solutions for the Biotherapeutics market, today reports another record year of sales in 2019. The Company recorded revenue growth from instrument sales and service support, with particular strength in the USA and China markets. It has also increased investment in company expansion across all divisions, employing more personnel in sales, application and service functions to maintain the existing high level of customer service, and in R&D to continue innovation in smart solutions for cell line development. Some other notable highlights of 2019 include:
- Strategic partnership with SAL Scientific to supply novel growth supplements for enhanced cell growth during cell line development
- Announcing €3.5M of funding, in a consortium including Valitacell and Microcoat, to develop and optimise a platform for accelerated identification of optimal cell lines for biological therapeutic manufacturing
Commenting on the 2019 performance, Aaron Figg, Director, said, “Solentim has had an excellent year. Our record commercial performance has enabled us to further invest in strategic expansion of the business and capitalise on future growth opportunities, and we look forward to continued expansion through 2020”.